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Background: Schizophrenia is a costly illness to treat, especially during a time of escalating
medicine inflation costs, putting a large economic strain on patients, their families and the
community. Treatment, however, can become more affordable through generic
substitution.
Objective: To determine the maximum potential cost-saving through generic substitution
for both originator and more expensive generic items while observing the prescribing
patterns of antipsychotics.
Method: Antipsychotic medicine usage was analysed retrospectively during the study
period 2008 to 2013 using data obtained from a nationally representative Pharmaceutical
Benefit Management Company. The study population consisted of 4410 patients with ICD-
10 codes (F20-F20.9) who had paid claims for an antipsychotic reimbursed from their
prescribed minimum benefits. Active ingredients were identified using the MIMS classifi-
cation system. Maximum potential cost savings were determined by substituting all orig-
inator and more expensive generic antipsychotic items with the cost of the least expensive
generic antipsychotic item available.
Results: Through generic substitution, a total potential cost-saving of ZAR4 642 685.45 could
be possible from 2008 to 2013. Average cost per items increased from
ZAR600.53 ± ZAR435.00 (median ZAR 539.82) in 2008 to ZAR1 196.59 ± ZAR 942.16 (median
ZAR 940.72) in 2013 and had a significant effect on patients' contribution, which increased
with 726.94% from 2005 to 2008. Psychiatrists prescribed the majority of antipsychotics.
Although generic items claimed increased by 60.31% during the study period, psychiatrists
still favoured non-generic prescribing (40.63%).
Conclusions: Potential economic benefits can be generated with generic substitution.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of Johannesburg Uni-
versity. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).cts; PMB, Prescribed Min
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Neuropsychiatric conditions are ranked third in their contri-
bution to the burden of disease in South Africa, after HIV/AIDS
and other infectious diseases (Bradshaw, Norman, &
Schneider, 2007; Lund et al., 2008). A study conducted by
Williams et al. (2008) revealed that 16.5% of all South Africans
suffer from common mental disorders, including, inter alia,
depression, anxiety and somatoform disorders. This figure,
however, did not include schizophrenia and bipolar mood
disorder (Williams et al., 2008). When costs of treatment for
psychiatric illnesses are compared, schizophrenia is the most
costly illness to treat (Emsley & Booysen, 2004). Without
healthcare coverage, treatment for schizophrenia can become
unaffordable, even if generic medicines are used (Lehman
et al. 2004). A rapid increase was observed in the percentage
of medical expenditures in association with prescription
drugs (Fischer & Avorn, 2003). In 2011, $12.6 billion was spent
on 54 million prescriptions issued for antipsychotics in the
United States of America (Leonhauser, 2012). Irrespective of its
economic strain on patients themselves, this disease also puts
a large economic burden on families, societies and healthcare
systems (Emsley & Booysen, 2004). For example, according to
Emsley and Booysen (2004), it could cost a family of a
schizophrenic patient approximately ZAR 498 771.00 per year
to take care of such an individual, while spending approxi-
mately 15 h a week taking care of these members.
South Africa spends 8.9% of its gross domestic product
(GDP) on health, which is relatively high compared to the 5%
recommended by the World Health Organization (WHO)
(WHO, 2016; Department of Health, 2011). According to the
South African National Treasury (2015), a total of ZAR
121 billion was spent on health for 2012/2013 (Department of
Health, 2011). Regardless of this rather high expenditure,
health outcomes compared to more or less the same middle-
income countries, remain poor (Department of Health, 2011).
In order to control healthcare costs in the private sector of
South Africa, a number of regulations, policies and pricing
interventions were put in place by the South African Gov-
ernment, inter alia, the National Drug Policy (NDP), the Medi-
cines and Related Substances Control Amendment Act (No 90
of 1997), Good Pharmacy Practice (GPP) and Good Marketing
Practice (GMP) rules, a transparent pricing structure and
certain pricing interventions such as mandatory generic
substitution, the establishment of the Single Exit Price (SEP)
for all medicine, and the Prescribed Minimum Benefits (PMBs)
and Chronic Disease List. The goal of the National Drug Policy,
published in 1996, was to “ensure an adequate and reliable
supply of safe, cost-effective drugs of acceptable quality to all
citizens of South Africa, and the rational use of drugs by
prescribers, dispensers and consumers” (South Africa, 1996).
The Medicines and Related Substances Control Amendment
Act No 90 of 1997, tabled in Parliament in May 1997, was
designed for the provision of more affordable medicines
(Deroukakis, 2007; South Africa, 1997). In Section 22F of this
act, which was implemented on 2 May 2003, generic substi-
tution was promulgated and states that a pharmacist is
required to dispense the generic alternative of a prescribed
medicine, unless the patient or the prescribing doctorexplicitly refuses the substitution, or if the price of the generic
product is higher than that of the branded or originator
product (Black, 2013; Deroukakis, 2007; South Africa, 1997).
The Medicines and Related Substances Act, Good Pharmacy
Practice (GPP) and Good Marketing Practice (GMP) rules
furthermore ensure that medicines are of good quality, that
medicines are safe and effective, that marketing takes place
according to a code of marketing and that medicine prices are
transparent and in accordance with single exit price (SEP)
regulations (Black, 2013). The Prescribed Minimum Benefit
(PMB) conditions listed by Council of Medical Schemes (CMS)
(CMS, 2009) is a set of well-defined benefits to make sure that
all medical schememembers have access to certainminimum
health services, regardless of the benefit option they have
selected, in order to be provided with continuous care, to
improve the health and well-being of a patient, to make
healthcare more affordable and to prevent restriction of ac-
cess to health insurance for high-risk individuals (CMS, 2010).
Medical aid schemes are obligated to cover diagnosis, medical
costs as well as cost of care of patients registered on the
chronic disease list of the PMB, provided that the prescribed
therapeutic algorithm is followed (CMS, 2009; Department of
Health, 2003). Schizophrenia is listed as one of these 27
chronic disease disorders in South Africa.
The single exit price in South Africa is set according to
benchmark prices of other international countries that follow
pricing systems closest to the system that is used in South
Africa. Department of Health (2015). New Zealand, Australia,
Canada and Spain were chosen as benchmarking countries
(Department of Health, 2015). The SEP may be applied to
products that are priced below the international benchmark
and may be increased up to the international benchmark, but
the SEP may not exceed the price of the benchmark
(Department of Health, 2015). The annual increase of SEP for
2008 was 6.5%; in 2009 SEP increased with 13.2%; and in 2010
SEP increased with 7.4% (Council for Medical Schemes, 2014).
In 2011, there was no increase in SEP (South Africa, 2011). An
annual adjustment wasmade in 2012 for the SEP of medicines
and scheduled substances where the South African Minister
of Health stated that SEP may only be applied to a maximum
of 2.14% as last stated on 9December 2011 (South Africa, 2012).
In 2013, a maximum of 5.8% was applied as last stated in 23
December 2012 (South Africa, 2013). In 2013, medicine
expenditure increased by 2% for cost per item from 2011
(Mediscor, 2013). A total of 42.2% of manufacturers that
represent approximately 83.3% of products sold in South Af-
rica took a 4% increase in SEP for January to May in 2013
(Mediscor, 2013). This increase in cost puts a large economic
strain on patients during a time of spiralling medication
inflation (Mediscor, 2013).
According to the WHO (2010), a generic drug is a pharma-
ceutical product or medicine item that is manufactured
without a licence from the innovator company and marketed
after the patent right of the specific drug has expired. These
generic medicines should be of the same formula (including,
inter alia, the same amount of active ingredient and the same
route of administration) while giving the same therapeutic
effectiveness than that of the originator medicine (Borgherini,
2003). Originator products have a higher cost than their
generic versions, which produce the same therapeutic effect
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low and middle-income countries, are substantially higher
than their generic alternatives (WHO, 2010). Typically, generic
substitutions are 20e90% cheaper than those of originator
medicines (Dunne, Shannon, Dunne, & Cullen, 2013). In 2013,
20% of overall medicine product costs were for original items
for which patents had already expired (Mediscor, 2013). This
raised concern, as average generic equivalents for all medi-
cine itemswere only ZAR96 per item, compared to the average
cost of all original items with expired patents at ZAR131
(Mediscor, 2013).
In this study, we aimed to determine the maximum po-
tential cost saving by substituting the average medicine cost
of more expensive generic and originator antipsychotic items
with that of the least expensive generic antipsychotic items
available on the database during the study period, while
observing the prescribing patterns of antipsychotics
(including, inter alia, prescriber speciality). Generic substitu-
tion poses the advantage of reducing treatment expenditure
for patients while maintaining the same quality of care
(Hamann, Mendel, Kissling, & Leucht, 2013).2. Method
2.1. Data source and study population
Medicine usage of antipsychotics for the treatment of
schizophrenia was analysed retrospectively using repeated
cross-sectional analysis, for the study period 1 January 2008 to
31 December 2013. Data were obtained from a Pharmaceutical
Benefit Management Company (PBM). A total of 8.78 million
individuals in South Africa were registered as members of
medical schemes in 2013 (Council for Medical Schemes, 2014),
of whom 1.7 million individuals were members of this na-
tionally representative PBM. All of South Africa's pharmacies
and 98% of all dispensing doctors are on this service provider
database.
Data fields used from the database included date of treat-
ment, active ingredients, direct medicine cost (total cost, SEP,
medical scheme contribution and patient contribution), trade
names of active ingredients and quantities.
All patients with ICD-10 codes F20-F20.9 (classification for
different types of schizophrenic diagnosis) with a claim
reimbursed from their prescribed minimum benefit for active
ingredients included in the MIMS classification system for
schizophrenia (N¼ 4410) were included in the study (Snyman,
2014). Antipsychotics were categorised according to four
pharmacological groups: phenothiazines, butyrophenones,
atypical antipsychotics and others (Snyman, 2014).
2.2. Measurements
Schizophrenia prevalence was determined as percentage of
the total patient population of the database. Total costs of
antipsychotics were determined as a percentage of the total
cost of medicine products of the database. Thereafter, the
average cost per item per patient was compared, in terms of
the medical scheme contribution and patient contribution as
well as the influence of the single exit price on the averagecost per item. Average costs per generic status (i.e. generic,
non-generic or originator) were compared, while observing
the medical scheme contribution and patient contributions.
Prevalence of antipsychotics prescribed based on generic
status and prescriber speciality was determined. The per-
centage change in the number of items and mean cost were
calculated by dividing the difference between the 2013 and
2008 values by the 2008 value and thenmultiplying it with 100.
For example: the percentage increase in mean cost ¼ [(Mean
cost 2013  mean cost 2008)/mean cost 2008] 
100 ¼ [(43.09  24.26)/24.26]  100 ¼ 77.62%.
The primary outcome of this study was to determine the
maximum potential cost saving in direct medicine costs for
patients per year by substituting all originator and more
expensive generic antipsychotic medicine items with the
mean cost of the least expensive generic antipsychotic med-
icine item during the year while observing the prescribing
patterns of antipsychotics (including, inter alia, prescriber
speciality). The differences in actual and substituted costs per
year were then summed to calculate the total potential cost
saving for the study period.
2.3. Statistical analysis
The SAS program version 9.3 (SAS Institute, Cary, NC,
2008e2013) was used for statistical analyses. Descriptive sta-
tistics included frequencies, means, standard deviations (SD),
medians and interquartile ranges, and 95% confidence in-
tervals (95% CI). Inferential statistics included analysis of
variance (ANOVA) with Tukey's HSD post-hoc test, which was
used to compare mean values between more than two inde-
pendent groups. Cohen's d-value was used to determine effect
sizes and was taken as practically significant if d  0.8. This
was only considered if there was a practical significance
p 0.001. Chi-square distributionmodelswere used to test the
distribution of the statistics of the population. Practical sig-
nificance was then determined by Cramer's V and values 0.1
were regarded as a small effect, 0.3 as a moderate effect and
0.5 as large effects.
2.4. Ethical considerations
This study was approved by the board of directors of the PBM
company, as well as the Health Research Ethics Committee of
the North-West University (NWU-00179-14-A1).3. Results
Table 1 describes the basic characteristics of the study popu-
lation. During the study period (2008e2013), the prevalence of
schizophrenia varied between 0.08% and 0.09% of the total
population on the database. The total direct cost for the
treatment of schizophrenia with antipsychotics ranged from
ZAR 6 374 096.29 in 2008 to ZAR 12 278 673.01 in 2013.
The majority of antipsychotics were prescribed by psy-
chiatrists (Table 2). Antipsychotic prescribing by general
medical practitioners decreased by 5.43% during the study
period, whereas that by neurologists and psychiatrists
increased with 0.52% and 4.80%, respectively. For the purpose
Table 2 e Prevalence of antipsychotics prescribed by generic statusa and prescriber speciality.
2008 n (%) 2009 n (%) 2010 n (%) 2011 n (%) 2012 n (%) 2013 n (%) Change in %
General medical practitioners 3371 (30.85) 4302 (29.76) 4326 (30.73) 3876 (30.48) 3145 (27.55) 2699 (25.42) 5.43
Non-genericb 2391 (70.93) 2311 (53.72) 2361 (54.58) 1633 (42.13) 1166 (37.07) 915 (33.90) 37.03
Originator 542 (16.08) 795 (26.36) 646 (14.93) 857 (22.11) 738 (23.47) 608 (22.53) 6.45
Generic 438 (12.99) 1196 (31.40) 1319 (30.49) 1386 (35.76) 1241 (39.46) 1176 (43.57) 30.58
Neurologists 299 (2.74) 258 (1.78) 248 (1.76) 259 (2.04) 392 (3.43) 346 (3.26) 0.52
Non-generic 123 (41.14) 109 (42.25) 137 (55.24) 97 (37.45) 118 (30.10) 62 (17.92) 23.22
Originator 142 (47.49) 68 (26.36) 57 (22.98) 83 (32.05) 90 (22.96) 101 (29.19) 18.30
Generic 34 (11.37) 81 (31.40) 54 (21.77) 79 (30.50) 184 (46.94) 183 (52.89) 41.52
Psychiatrists 6452 (59.05) 8702 (60.19) 8375 (59.50) 7812 (61.44) 7053 (61.79) 6779 (63.85) 4.80
Non-generic 4882 (75.67) 5540 (63.66) 5549 (66.26) 4076 (52.18) 3107 (44.05) 2754 (40.63) 35.04
Originator 846 (13.11) 1320 (15.17) 951 (11.36) 1700 (21.76) 1519 (21.54) 1554 (22.92) 9.81
Generic 724 (11.22) 1842 (21.17) 1875 (22.39) 2036 (26.06) 2427 (34.41) 2471 (36.45) 25.23
Other 804 (7.36) 1195 (8.26) 1127 (8.01) 768 (6.04) 824 (7.22) 793 (7.47) 0.11
Non-generic 606 (75.38) 602 (50.38) 637 (56.52) 315 (41.02) 352 (42.72) 307 (38.71) 36.67
Originator 95 (11.81) 307 (25.69) 251 (22.27) 224 (29.17) 179 (21.72) 174 (21.94) 10.13
Generic 103 (12.81) 286 (23.93) 239 (21.21) 229 (29.82) 293 (35.56) 312 (39.34) 26.53
a Generic status: generic; non-generic; originator.
b Non-generic item: an originator product of which the patent have not yet expired and therefore no generic equivalent product is available.
Table 1 e Basic characteristics of the study population.
2008 2009 2010 2011 2012 2013
Patients, N 758 505 1 033 057 968 158 864 977 815 810 809 857
Schizophrenic
patients, n (%)
637 (0.08) 834 (0.08) 823 (0.09) 766 (0.09) 713 (0.09) 637 (0.08)
Database cost (ZAR), N 1 782 920 908.9 2 505 739 217.5 2 457 045 952.7 2 008 943 287.0 1 838 950 559.0 3 604 278 997.0
Cost for schizophrenia
patients (ZAR), n (%)
6 374 096.29 (0.36) 8 926 490.81 (0.36) 9 477 421.93 (0.39) 8 534 989.46 (0.42) 7 055 848.88 (0.38) 12 278 673.01 (0.34)
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product of which the patent has not yet expired and therefore
no generic equivalent product was available. A general
breakdown of the prescribing patterns of antipsychotics by
generic status shows that the prescribing of non-generic items
decreased by 35.21% overall, whereas that of originator and
generic items increased with 8.08% and 27.12%, respectively,
during the study period. Prescribing of generic antipsychotics
by general medical practitioners, neurologists and psychia-
trists increased by 30.58%, 41.52% and 25.23%, respectively,
from 2008 to 2013 (Table 2). The prescribing of non-generic
items by all prescribers decreased during the study period;
however, psychiatrists still slightly favoured prescribing of
non-generic items during 2013 (40.63%). The majority of pre-
scriptions by general medical practitioners, neurologists and
all other prescribers were for non-generic items.
The cost per antipsychotic medicine item consists of a
drug's SEP, scheme contribution and patient contribution.
These, as well as a breakdown of mean costs stratified by
generic status are presented in Table 3. The mean cost per
item increased by 99.26% from ZAR 600.53 ± ZAR 435.00 (95%
CI 566.68e634.38) in 2008 to ZAR 1196.59 ± ZAR 942.16 (95% CI
1123.29e1269.90) in 2013 (p < 0.001; Cohen's d-value ¼ 1.01)
(Table 3). The mean SEP per item increased with 77.62% from
ZAR24.26 ± ZAR 67.84 (95% CI 18.98e29.53) in 2008 to ZAR
43.09 ± ZAR165.44 (95% CI 555.89 ± 555.89) in 2013. Although
the mean cost covered by medical schemes stayed more or
less the same, a practically significant increase of 726.94%occurred in the co-payment of patients from ZAR 77.48 ± ZAR
123.76 (95% CI 67.86e87.11) in 2008 to ZAR 640.71 ± ZAR 518.19
(95% CI 600.39e681.02) in 2013 (p < 0.001; Cohen's d-
value ¼ 2.28).
Stratification of the mean cost per antipsychotic medicine
item by generic status showed that the mean cost of generics
increased with 219.52% from 2008 to 2013 (Cohen's d-
value ¼ 1.02), whereas that of originator and non-generic
items increased by 136.69% (Cohen's d-value ¼ 0.77) and
106.45% (Cohen's d-value ¼ 0.56), respectively (Table 3). Mean
patient co-payments for non-generic and generic drugs
increased by 784.17% and 798.78%, respectively, over the study
period (Cohen's d-value > 0.8), whereas that of originator
drugs increased by 444.93% (Cohen's d-value ¼ 1.1). The SEP
increased with 163.35% for non-generic items (Cohen's d-
value ¼ 0.18) and 105.66% for generic items (Cohen's d-
value ¼ 0.89). Scheme contributions for non-generics
remained relatively the same (Cohen's d-value ¼ 0.08), while
increasing by 36.51% for originators (Cohen's d-value ¼ 0.35)
and 91.84% for generics (Cohen's d-value ¼ 0.70).
Availability of generic alternatives increased within the
study period; however, from the 18 antipsychotics currently
available in the South African market (listed in Table 4), only
five had generic alternatives on the database during the study
period. These included; clozapine, haloperidol, olanzapine,
quetiapine and risperidone. The total costs for originator and
generic items in 2008 accrued to ZAR 281 946.66 (Table 5). If all
originator andmore expensive generic itemswere substituted
Table 3 e Cost per antipsychotic medicine item, stratified by generic status.a
2008 mean
(95% CI)
2009 mean
(95% CI)
2010 mean
(95% CI)
2011 mean
(95% CI)
2012 mean
(95% CI)
2013 mean
(95% CI)
p-value
(Cohen's d)
Cost per item (ZAR) 600.53 ± 435.00
(566.68e634.38)
665.72 ± 513.66
(630.80e700.62)
696.91 ± 558.92
(658.67e735.16)
698.29 ± 527.35
(660.89e735.70)
628.76 ± 484.63
(593.13e664.40)
1196.59 ± 942.16
(1123.29e1269.90)
<0.001
(1.01)
Non-generic 689.80 ± 487.20
(649.80e729.80)
779.90 ± 618.50
(731.90e618.40)
812.40 ± 633.31
(762.60e862.26)
812.35 ± 640.53
(758.80e865.90)
717.89 ± 682.45
(651.96e783.82)
1424.06 ± 1303.76
(1292.20e1555.91)
(0.56)
Originator 412.70 ± 353.40
(362.30e463.20)
442.70 ± 363.20
(401.20e363.20)
581.0 ± 587.26
(508.74e653.31)
830.90 ± 659.29
(760.26e901.55)
620.76 ± 512.91
(559.87e681.64)
976.80 ± 733.79
(888.38e1065.21)
(0.77)
Generic 267.54 ± 258.30
(226.70e308.40)
418.10 ± 324.20
(383.70e324.20)
410.90 ± 339.70
(375.60e446.31)
457.69 ± 317.91
(425.58e489.80)
442.93 ± 309.30
(413.08e472.77)
854.85 ± 576.13
(797.71e911.99)
(1.02)
SEP (ZAR) 24.26 ± 67.84
(18.98e29.53)
30.20 ± 102.89
(23.21e37.18)
33.39 ± 105.75
(26.16e40.63)
35.49 ± 117.55
(27.16e43.83)
33.85 ± 118.04
(25.17e42.52)
43.09 ± 165.44
(30.22e55.96)
0.096
(0.16)
Non-generic 30.07 ± 84.73
(23.12e37.03)
43.78 ± 139.77
(32.94e54.62)
47.42 ± 146.94
(35.86e58.98)
50.69 ± 151.97
(37.99e63.40)
61.48 ± 196.36
(42.51e80.44)
79.19 ± 266.22
(52.26e106.11)
(0.18)
Originator 12.68 ± 16.17
(10.37e14.99)
14.42 ± 17.41
(12.43e16.41)
17.06 ± 19.87
(14.62e19.51)
22.79 ± 18.15
(20.84e24.73)
16.58 ± 14.47
(14.86e18.29)
12.69 ± 12.70
(11.16e14.22)
0
Generic 4.42 ± 4.81
(3.66e5.18)
8.02 ± 6.15
(7.37e8.68)
7.85 ± 5.83
(7.25e8.46)
9.53 ± 5.88
(8.94e10.12)
9.15 ± 5.46
(8.63e9.68)
9.09 ± 5.41
(8.56e9.63)
(0.86)
Scheme
contribution (ZAR)
523.05 ± 403.05
(491.69e554.41)
560.85 ± 560.84
(528.59e593.09)
591.24 ± 591.24
(556.48e626.01)
607.73 ± 607.73
(572.92e642.54)
541.56 ± 541.56
(509.71e573.41)
555.89 ± 555.89
(521.61e590.16)
0.006
(0.07)
Non-generic 602.27 ± 462.74
(564.29e640.23)
666.02 ± 577.08
(621.26e710.78)
691.39 ± 584.12
(645.44e737.35)
714.18 ± 603.72
(663.71e764.66)
613.87 ± 605.70
(555.35e672.39)
650.32 ± 619.99
(587.62e713.02)
(0.08)
Originator 312.33 ± 268.52
(274.01e350.66)
305.77 ± 279.83
(273.81e337.72)
436.09 ± 537.97
(369.88e502.31)
690.75 ± 610.50
(625.33e756.16)
465.55 ± 405.01
(417.47e513.63)
429.64 ± 336.11
(389.14e470.14)
(0.35)
Generic 219.22 ± 216.94
(184.91e253.53)
361.03 ± 304.01
(328.74e393.31)
356.28 ± 309.37
(324.08e388.48)
422.59 ± 299.28
(392.36e452.82)
412.96 ± 297.57
(384.25e441.67)
420.56 ± 286.90
(392.15e448.97)
(0.70)
Patient
co-payment (ZAR)
77.48 ± 123.76
(67.86e87.11)
104.87 ± 174.52
(93.00e116.73)
105.67 ± 185.84
(92.96e118.39)
90.57 ± 154.46
(79.61e101.52)
87.20 ± 150.32
(76.15e98.26)
640.71 ± 518.19
(600.39e681.02)
<0.001
(2.28)
Non-generic 87.51 ± 143.27
(75.76e99.27)
113.91 ± 208.92
(97.70e130.11)
121.04 ± 227.90
(103.11e138.97)
98.17 ± 182.35
(82.92e113.41)
104.02 ± 198.15
(84.88e123.17)
773.74 ± 704.78
(702.46e845.01)
(0.97)
Originator 100.41 ± 223.58
(68.50e132.32)
136.94 ± 169.20
(117.62e156.26)
144.93 ± 214.75
(118.50e171.36)
140.16 ± 197.98
(118.94e161.37)
155.21 ± 217.18
(129.42e180.99)
547.16 ± 421.51
(496.37e597.95)
(1.06)
Generic 48.32 ± 141.35
(25.97e70.68)
57.09 ± 113.65
(45.02e69.16)
54.68 ± 104.21
(43.84e65.53)
35.10 ± 60.61
(28.98e41.23)
29.97 ± 29.97
(25.09e34.84)
434.29 ± 294.11
(405.12e463.46)
(1.31)
a Generic status: generic; non-generic; originator.
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able, a potential cost saving of ZAR 106 855.59 (37.90%) could
have been generated during 2008. Similarly, potential annual
cost-savings of 25.72%, 33.64%, 47.80%, 41.47% and 39.29%,
respectively, would have been possible from 2009 to 2013. A
total of ZAR 4 642 685.00 could potentially have been saved
over the six-year study period if all originator and more
expensive antipsychotic generic items were substituted with
the least expensive generic antipsychotic item available on
the database for each year.4. Discussion
Treatment for schizophrenia is extremely costly (Emsley &
Booysen, 2004), and therefore patients' health expenditures
can be reduced by developing a cost-saving plan through
generic substitution (Hamann et al., 2013). By using generic
medication, at a lower cost and assured quality of their orig-
inator equivalent, health outcomes for both patients and
health systems can be achieved at a lower cost.
For our study, atypical antipsychotics had more generic
equivalents (clozapine, olanzapine, quetiapine, risperidone)
as opposed to typical antipsychotics (haloperidol), supporting
studies from the literature that atypical antipsychotics areleading the market (Leonhauser, 2012). However, no generic
equivalents were available for the phenothiazines and
‘others’ (e.g. sulpiride, zuclopenthixol decanoate, flupenthixol
and clothiapine) group on the dataset during the study period.
The low number of generic alternatives for quetiapine and
olanzapine could be due to patent protection during our study
period. These expired in 2011 for olanzapine (Zyprexa®) and in
2012 for quetiapine (Seroquel®) (De Ruiter & Holston, 2012).
Based on the Mediscor annual report of 2013/2014, 20% of
medicine items in total claimed during 2013 were originator
products (Mediscor, 2013). Medical aid schemes make use of
reference drugs for each therapeutic class to determine the
maximum price that may be reimbursed (McLeod & Ramjee,
2006). If the cost of the drug dispensed is higher than the
price of the reference drug, then the patient has to pay the
difference in price (McLeod & Ramjee, 2006). Antipsychotics
claimed during 2013 were the most expensive, even with
generic substitutions (Table 4). The national single exit price
increased initially with 6.5% annually from 2008, then 13.2%
(2009), 7.4% (2010), 0% (2011), 2.14% (2012) and 5.8% (2013),
respectively, affecting the dispensing fee that directly influ-
enced the median cost per item (CMS, 2014; Government
Gazette, 2011; Government Gazette, 2012; Government
Gazette, 2013; Mediscor, 2013). A 5.8% increase in the SEP
was allowed in 2013, causing an overall 2% increase in the
Table 4 e Antipsychotics available in South Africa for the treatment of schizophrenia.
Pharmacological class Active ingredient Oral Injection Generic statusa
Phenothiazine
(injections are classified
according to trade names)
Chlorpromazine Yes No Non-genericb
Fluphenazine No Yes (Modecate®) Non-generic
Pimozide Yes No Non-generic
Prochlorperazine Yes No Generic
Trifluoperazine Yes No Non-generic
Butyrophenones
(injections are classified
according to trade names)
Haloperidol Yes Yes (Serenace®) Non-generic,
originator, generic
Atypical antipsychotics Aripiprazole Yes No Non-generic
Risperidone Yes No Non-generic,
originator, generic
Clozapine Yes No Originator and Generic
Quetiapine Yes No Non-generic
(2008e2010),
Generic (from 2011)
Ziprasidone Yes Yes (Geodon®) Non-generic
Paliperidone Yes No Non-generic
Olanzapine Yes Yes (Zyprexa®) Non-generic
(2008e2010),
Generic (from 2011)
Amisulpiride Yes No Non-generic
Others Sulpiride Yes No Non-generic
Zuclopenthixol Yes Yes (Clopixol®) Non-generic
Clothiapine Yes Yes (Etomine®) Non-generic
Flupenthixol Yes Yes (Fluanxol®)
(Fluanxol depot®)
Non-generic
a Generic status: generic; non-generic; originator.
b Non-generic item: an originator product of which the patent have not yet expired and therefore no generic equivalent product is available.
Table 5 e Maximum potential cost-savings through generic substitution.
2008 2009 2010 2011 2012 2013
Clozapine
Medicine items, n 201 249 219 211 661 363
Total cost (ZAR) 113 167.57 159 148.45 177 826.18 191 209.42 403 292.65 408 437.66
Potential saving
(ZAR) (%)
32 916.31 (29.09) 44 045.71 (27.68) 71 411.89 (40.16) 72 068.27 (37.69) 261 891.53 (64.94) 132 594.46 (32.46)
Haloperidol
Medicine items, n 5 15 25 10 24 43
Total cost (ZAR) 1031.97 2199.43 3138.88 1481.66 5854.48 12 171.93
Potential saving
(ZAR) (%)
706.37 (68.45) 1091.23 (49.61) 1418.63 (45.20) 769.96 (51.97) 4118.08 (70.34) 4049.66 (33.27)
Olanzapine
Medicine items, n 1082 1084 752
Total cost (ZAR) 1 299 877.83 826 591.08 1 004 361.17
Potential saving
(ZAR) (%)
710 044.10 (5.46) 289 141.70 (34.98) 200 917.80 (20.00)
Quetiapine
Medicine items, n 721 720
Total cost (ZAR) 351 164.33 607 153.41
Potential saving
(ZAR) (%)
177 121.20 (50.44) 274 303.70 (45.19)
Risperidone
Medicine items, n 224 389 1927 1792 1483 1487
Total cost (ZAR) 167 747.12 1 326 960.99 1 152 382.69 1 068 857.11 921 614.13 1 632 547.04
Potential saving
(ZAR) (%)
73 232.91 (43.66) 337 699.40 (25.45) 375 693.30 (32.60) 441 389.50 (41.30) 308 024.20 (33.42) 828 035 (50.72)
Total cost (ZAR) 281 946.66 1 488 308.87 1 333 347.70 2 561 426.10 2 508 516.70 3 664 671.20
Total potential
saving (ZAR) (%)
106 855.59 (37.90) 382 836.34 (25.72) 448 523.82 (33.64) 1 224 272.20 (47.80) 1 040 297 (41.47) 1 439 900.50 (39.29)
h e a l t h s a g e s ondh e i d 2 1 ( 2 0 1 6 ) 3 5 6e3 6 3 361
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costs for 2013 (Mediscor, 2013).
Patient contribution for all antipsychotics (generics, non-
generics and originators alike) increased significantly from
2008 to 2013 compared to both the average household inflation
in South Africa, as well as the increase in earning power of the
households (Statistics South Africa, 2016). This could be due to
changes inmedical scheme benefit packages and formularies,
medical inflation, possible use of non-designated service
providers, as well as additional costs charged by the provider
that were in disagreement with the medical scheme rate or
dispensing fee for the year (Mediscor, 2013). Research has,
however, shown that co-payments have an immediate and
persistent deterrent effect on the use of psychotherapeutic
drugs, increasing the likelihood that patients will choose not
to pay and to stop taking prescribed drugs (Reeder & Nelson,
1985; Treur, Heeg, M€oller, Schmeding, & Van Hout, 2009),
resulting in increases in patient visits to community mental
health centres, use of emergency mental health services and
partial hospitalisation (Hynd et al., 2008; Soumerai,
McLaughlin, Ross-Deghan, Casteris, & Bollini, 1994).
According to Fischer and Avorn (2003), a potential annual
cost-saving of a quarter to half a billion dollars is possible
when all originator prescription drugs are substituted with
generic brands. This observation was confirmed in our study
where it was found that approximately ZAR 4.6 million could
have been saved over the six-year period if antipsychotic
drugs for the treatment of schizophrenia were generically
substituted. Psychiatrists, however, are not always willing to
consider that medication may be substituted with their
generic equivalents (Hamann et al., 2013). Reasons stated
against generic substitution includes that physicians have
been found to believe that originator medicine items are
more effective and have a higher standard of manufacturing
than their generic versions (Fischer & Avorn, 2003; Shrank
et al., 2011), vague attitudes towards properties of generics
and branded drugs as well as by ‘non-evidence based’ factors
such as uncertainty in tolerance (Hamann et al., 2013).
Furthermore, patients themselves are not always willing to
use generic equivalents. For example, Roman (2009) found
that 73% of patients treated with oral antipsychotics would
refuse generic substitution when given the option by a
pharmacist. Schizophrenic patients, in particular, are often
reluctant to change and may become suspicious, paranoid,
delusional or even hostile when changing their medicine to a
generic version (Treur et al., 2009). Reasons stated against the
use of generics in general include that generic items appear
differently (different colours, odd shapes etc.) than the orig-
inator items, confusing patients, especially the elderly
(Dunne et al., 2013) Therefore, it is encouraged that generic
products have the same appearance than their originators
(Posner & Griffin, 2011).5. Conclusion
This study confirmed the potential economic benefits of using
generics. It can be concluded that if only 45% of medicine
items were dispensed using generic substitution, which, ac-
cording to Mediscor, is the actual rate for generic substitutionin South Africa, then a total of ZAR 2 089 208.20 could still have
been saved during the study period. Due to patent protection
on drugs, there is the probability that the number of generic
alternatives will increase for antipsychotics in the future.
However, with the rather large increase in patient contribu-
tion towards antipsychotics, it is clear that even generic drugs
may soon be unaffordable for patients, which can also affect
patients' adherence. It is therefore necessary that alternative
and innovative cost-saving methods be investigated.6. Limitations
When patients used varying providers, all the necessary
claims were not captured (e.g. ‘out-of-pocket’ payments,
hospitalisation etc.) as these claims data were lost to the
database and therefore not available for analyses. External
validity was also limited as only one database was used for
analyses and was therefore not representative of the South
African market as a whole.Funding
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